Terms: = Prostate cancer AND CREBBP, CBP, 1387, ENSG00000005339, RSTS, RTS AND Treatment
57 results:
1. Discovery of cbpD-409 as a Highly Potent, Selective, and Orally Efficacious cbp/p300 PROTAC Degrader for the treatment of Advanced prostate cancer.
Chen Z; Wang M; Wu D; Zhao L; Metwally H; Jiang W; Wang Y; Bai L; McEachern D; Luo J; Wang M; Li Q; Matvekas A; Wen B; Sun D; Chinnaiyan AM; Wang S
J Med Chem; 2024 Apr; 67(7):5351-5372. PubMed ID: 38530938
[TBL] [Abstract] [Full Text] [Related]
2. cbp/p300 Degrader: A Promising Therapeutic Strategy for treatment of prostate cancer and Beyond.
Hu J; Xu Y
J Med Chem; 2024 Apr; 67(7):5272-5274. PubMed ID: 38517344
[TBL] [Abstract] [Full Text] [Related]
3. Discovery of cbpD-268 as an Exceptionally Potent and Orally Efficacious cbp/p300 PROTAC Degrader Capable of Achieving Tumor Regression.
Chen Z; Wang M; Wu D; Bai L; Xu T; Metwally H; Wang Y; McEachern D; Zhao L; Li R; Takyi-Williams J; Wang M; Wang L; Li Q; Wen B; Sun D; Wang S
J Med Chem; 2024 Apr; 67(7):5275-5304. PubMed ID: 38477974
[TBL] [Abstract] [Full Text] [Related]
4. Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1/STAT4 pathway.
Cheng B; Li L; Luo T; Wang Q; Luo Y; Bai S; Li K; Lai Y; Huang H
J Exp Clin Cancer Res; 2024 Mar; 43(1):67. PubMed ID: 38429845
[TBL] [Abstract] [Full Text] [Related]
5. Androgen Receptor Variants Confer Castration Resistance in prostate cancer by Counteracting Antiandrogen-Induced Ferroptosis.
Sun R; Yan B; Li H; Ding D; Wang L; Pang J; Ye D; Huang H
Cancer Res; 2023 Oct; 83(19):3192-3204. PubMed ID: 37527336
[TBL] [Abstract] [Full Text] [Related]
6. Targeting CDCP1 gene transcription coactivated by BRD4 and cbp/p300 in castration-resistant prostate cancer.
Ji D; Shang G; Wei E; Jia Y; Wang C; Zhang Q; Zeng L
Oncogene; 2022 Jun; 41(23):3251-3262. PubMed ID: 35513563
[TBL] [Abstract] [Full Text] [Related]
7. Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as cbp Bromodomain Inhibitors for the treatment of prostate cancer.
Xiang Q; Wang C; Wu T; Zhang C; Hu Q; Luo G; Hu J; Zhuang X; Zou L; Shen H; Wu X; Zhang Y; Kong X; Liu J; Xu Y
J Med Chem; 2022 Jan; 65(1):785-810. PubMed ID: 34962793
[TBL] [Abstract] [Full Text] [Related]
8. Synthesis and Biological Evaluation of Spirocyclic Chromane Derivatives as a Potential treatment of prostate cancer.
Feng L; Yu S; Wang H; Yang S; Li X; Dai H; Zhao L; Jiang C; Wang Y
Molecules; 2021 May; 26(11):. PubMed ID: 34070610
[TBL] [Abstract] [Full Text] [Related]
9. A noncanonical AR addiction drives enzalutamide resistance in prostate cancer.
He Y; Wei T; Ye Z; Orme JJ; Lin D; Sheng H; Fazli L; Jeffrey Karnes R; Jimenez R; Wang L; Wang L; Gleave ME; Wang Y; Shi L; Huang H
Nat Commun; 2021 Mar; 12(1):1521. PubMed ID: 33750801
[TBL] [Abstract] [Full Text] [Related]
10. MYC-Mediated Ribosomal Gene Expression Sensitizes Enzalutamide-resistant prostate cancer Cells to EP300/crebbp Inhibitors.
Furlan T; Kirchmair A; Sampson N; Puhr M; Gruber M; Trajanoski Z; Santer FR; Parson W; Handle F; Culig Z
Am J Pathol; 2021 Jun; 191(6):1094-1107. PubMed ID: 33705753
[TBL] [Abstract] [Full Text] [Related]
11. Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the cbp-p300 Complex, Leading to Resistance in prostate cancer Cells.
Pan W; Zhang Z; Kimball H; Qu F; Berlind K; Stopsack KH; Lee GM; Choueiri TK; Kantoff PW
Clin Cancer Res; 2021 Apr; 27(7):2087-2099. PubMed ID: 33495313
[TBL] [Abstract] [Full Text] [Related]
12. Targeting the p300/cbp Axis in Lethal prostate cancer.
Welti J; Sharp A; Brooks N; Yuan W; McNair C; Chand SN; Pal A; Figueiredo I; Riisnaes R; Gurel B; Rekowski J; Bogdan D; West W; Young B; Raja M; Prosser A; Lane J; Thomson S; Worthington J; Onions S; Shannon J; Paoletta S; Brown R; Smyth D; Harbottle GW; Gil VS; Miranda S; Crespo M; Ferreira A; Pereira R; Tunariu N; Carreira S; Neeb AJ; Ning J; Swain A; Taddei D; ; Schiewer MJ; Knudsen KE; Pegg N; de Bono JS
Cancer Discov; 2021 May; 11(5):1118-1137. PubMed ID: 33431496
[TBL] [Abstract] [Full Text] [Related]
13. Current development of cbp/p300 inhibitors in the last decade.
He ZX; Wei BF; Zhang X; Gong YP; Ma LY; Zhao W
Eur J Med Chem; 2021 Jan; 209():112861. PubMed ID: 33045661
[TBL] [Abstract] [Full Text] [Related]
14. Technical considerations for positioning and placement of a transperineal ultrasound probe during prostate radiotherapy.
Pang EPP; Knight K; Leung RW; Wang MLC; Chan JWS; Low GK; Seah IKL; Atan MAB; Chai JYH; Ng GC; Yang TC; Tuan JKL
J Med Radiat Sci; 2021 Jun; 68(2):196-202. PubMed ID: 33017863
[TBL] [Abstract] [Full Text] [Related]
15. Acetylation-mediated degradation of HSD17B4 regulates the progression of prostate cancer.
Huang H; Liu R; Huang Y; Feng Y; Fu Y; Chen L; Chen Z; Cai Y; Zhang Y; Chen Y
Aging (Albany NY); 2020 Jul; 12(14):14699-14717. PubMed ID: 32678070
[TBL] [Abstract] [Full Text] [Related]
16. Histone Acetyltransferase (HAT) P300/cbp Inhibitors Induce Synthetic Lethality in PTEN-Deficient Colorectal cancer Cells through Destabilizing AKT.
Liu Y; Yang EJ; Shi C; Mou PK; Zhang B; Wu C; Lyu J; Shim JS
Int J Biol Sci; 2020; 16(11):1774-1784. PubMed ID: 32398948
[TBL] [Abstract] [Full Text] [Related]
17. Tetramethylpyrazine reduces prostate cancer malignancy through inactivation of the DPP10‑AS1/cbp/FOXM1 signaling pathway.
Zhou Y; Zhou Z; Ji Z; Yan W; Li H; Yu X
Int J Oncol; 2020 Jul; 57(1):314-324. PubMed ID: 32319592
[TBL] [Abstract] [Full Text] [Related]
18. p300/cbp inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.
Liu J; He D; Cheng L; Huang C; Zhang Y; Rao X; Kong Y; Li C; Zhang Z; Liu J; Jones K; Napier D; Lee EY; Wang C; Liu X
Oncogene; 2020 May; 39(19):3939-3951. PubMed ID: 32203167
[TBL] [Abstract] [Full Text] [Related]
19. Implementing daily soft tissue image guidance with reduced margins for post-prostatectomy radiotherapy: research-based changes to clinical practice.
Bell LJ; Eade T; Hruby G; Bromley R; Kneebone A
J Med Radiat Sci; 2019 Dec; 66(4):259-268. PubMed ID: 31680490
[TBL] [Abstract] [Full Text] [Related]
20. Y08197 is a novel and selective cbp/EP300 bromodomain inhibitor for the treatment of prostate cancer.
Zou LJ; Xiang QP; Xue XQ; Zhang C; Li CC; Wang C; Li Q; Wang R; Wu S; Zhou YL; Zhang Y; Xu Y
Acta Pharmacol Sin; 2019 Nov; 40(11):1436-1447. PubMed ID: 31097763
[TBL] [Abstract] [Full Text] [Related]
[Next]
